TrialAnnals of hematology2025

Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.

Gerwin Huls et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.